Adagio Medical posts Q2 2026 net loss of $6.7M; submits PMA for VT ablation system

Adagio Medical Holdings, Inc.

2026-Q2 EPS reported -$0.62

Net loss widened to $6.7M ($0.30/share) from $3.9M ($0.26) a year ago; revenue nil.
R&D spend $2.5M vs $2.0M; SG&A $2.5M vs $2.4M; cash $7.7M at June 30.
FULCRUM-VT trial (209 pts): 2.4% MAE, 84% freedom from ICD shock, 78% reduced/discontinued antiarrhythmics.
Submitted PMA to FDA for vCLAS Ventricular Ablation System for monomorphic VT in structural heart disease.
First patient treated with next-gen vCLAS Ultra catheter under FDA Expanded Access at Penn.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.